The University of Chicago Vitreoretinal Service
Fellowship in the Diseases and Surgery of the Retina, Macula and Vitreous
It is with great pleasure that my partners and I welcome you to the University of Chicago’s Retina Service. Since 2005, we have been training exceptionally skilled vitreoretinal surgeons. Our Vitreoretinal Service has a long track record of offering state of the art vitreoretinal surgery, providing exceptional patient care, and conducting clinical research. Furthermore, we are involved in numerous educational efforts at the local and national level.

We are very passionate about training the future generation of vitreoretinal fellows. All of our attending physicians bring with them years of experience, allowing them to pass skills and techniques onto our fellows each year. The diversity of training includes both university and private practice settings in several locations. This varied exposure leads to an educational, fulfilling experience for the fellows. Along with obtaining excellent clinical and surgical skills, our fellows learn how to balance a busy clinic and OR schedule in an efficient and economically sensible fashion. Furthermore, our Service strongly encourages fellow participation in clinical research and FDA registration trials.

We are also proud of the AUPO and ASRS accreditation of our vitreoretinal fellowship program. My partners and I are committed to fellowship training and will continue to strive to make our fellowship a great experience that yields excellent vitreoretinal surgeons for years to come.

Seenu M. Hariprasad, MD
Shui-Chin Lee Endowed Professor
Ophthalmologist-in-Chief and Chair
Director, Fellowship in the Diseases and Surgery of the Retina, Macula, and Vitreous
Several, generous philanthropic donors have provided the additional, ongoing support necessary for sustaining our fellowship training program.

Snyder Family Fellowship Endowment Fund
Established in 2014, the Snyder Family Fellowship Fund was used by the University to establish and endow the Snyder Family Fellowship in the Diseases, and Surgery of the Retina, Macula and Vitreous. This Fellowship supports postgraduate Fellows undergoing specialized training in Vitreoretinal Surgery in the Department of Ophthalmology and Visual Science under the direction of Seenu M. Hariprasad, MD.

Mr. John Snyder’s desire to give to the Department of Ophthalmology and Visual Science stems from personal experience; his father and uncle lost their eyesight from macular degeneration. “When people begin losing their eyesight at an advanced age, it is harder for them to adapt through learning Braille or using assistive technologies,” Snyder notes. “My father started losing his ability to read, and since he was a lawyer, books were his life,” Snyder says. “He eventually had to use a magnifying glass and was hardly able to see the television. It affected his mental outlook, and he declined very rapidly.”

Snyder wants to help other future patients – including his children, who are genetically predisposed to macular degeneration – to avoid his father’s fate. Snyder is optimistic that Dr. Hariprasad and the University of Chicago medicine’s vitreoretinal service, with assistance from generous donations, will be able to train more doctors and scholars on how to better prevent and treat diseases of the retina.

Shui-Chin Lee Fellowship Endowment Fund
Established in 2014, the Shui-Chin Lee Fellowship Endowment Fund was used by the University to establish and endow the Shui-Chin Lee Fellowship in the Diseases and Surgery of the Retina, Macula, and Vitreous. The Fellowship supports postgraduate Fellows undergoing specialized training in Vitreoretinal Surgery in the Department of Ophthalmology and Visual Science under the direction of Seenu M. Hariprasad, MD.

Perhaps the most important idea that Mr. Shui-Chin Lee taught his children was that while acquiring knowledge was imperative, the way knowledge and information were internally processed and organized mattered more. To that end, he encouraged them to immerse themselves in math, science and technology. This allowed his children to cultivate their ability in dialectic analysis, a philosophical tool that emphasizes reason and deduction in order to verify and probe for the highest of all concepts: truth. It is the pursuit of this truth that ultimately drives academics and its sciences; it is the impetus of the research we perform in our Vitreoretinal Service, to seek answers to questions that impact vision and, therefore, human life.

Seenu M. Hariprasad, M.D. Vitreoretinal Surgical Fellows Family Fund
This award was created in 2022 by previous retina fellows in honor of Dr. Seenu M. Hariprasad, M.D., to serve as a legacy for his extraordinary leadership and guidance in the Department of Ophthalmology and Visual Science at the University of Chicago. The funds from this endowment allow for an annual guest speaker as well as an award to the resident who demonstrates strong skills in the area of retinal disease.

Benefactors

The Snyder Family Fellowship Endowment Fund
The Shui-Chin Lee Fellowship Endowment Fund
The Seenu M. Hariprasad, M.D. Vitreoretinal Surgical Fellows Family Fund

Non-endowment Fellowship Support
Several, generous philanthropic donors have provided the additional, ongoing support necessary for sustaining our fellowship training program.

Mr. Stephen Brenner
Mrs. Kathryn Earley and Mr. Robert Earley
Mr. and Mrs. Richard Hill
Mrs. Rosa O’Connor
Mr. and Mrs. John Paleczny
Dr. Robert W. Ridley
Mr. George R. and Mrs. Sally Rieger
Mrs. Ruth Ultmann

Mr. Ray A. Wiora
Dr. Daniel Kiernan and Mrs. Kristi Carpenter-Kiernan
Drs. Veeral and Monica Sheth
Mrs. Michele and Mr. Noel Moore
Mrs. Cindy and Mr. Richard Strup
Mr. Greg Boecker
Ms. Helen Oros
Mrs. Mignon and Mr. John Snyder, Jr.
The Department of Ophthalmology offers a two-year vitreoretinal fellowship that is both AUPO and ASRS compliant. The focus of this fellowship is to evaluate, diagnose, and medically or surgically manage vitreoretinal diseases. The retina fellows work very closely with the retina faculty and retina resident as part of the “retina team” to run the service. Dr. Hariprasad is deeply involved in education of fellows both years.

The First Year:

The first year of the fellowship is primarily devoted to the diagnosis and treatment of vitreoretinal disease and ROP. The first year fellow gets extensive hands-on experience in the operating room. Rotations in this year consist of retina clinics at the University of Chicago along with the private practice retina service headed by Dr. Shaun Ittiara and Dr. Paul Chiranand. Additionally, the first year fellow spends time under the tutelage of Dr. Alexis Warren, Dr. Michael Blair and Dr. Sarah Rodriguez, learning the diagnosis and management of complex pediatric vitreoretinal pathology such as ROP.

During the first year, the fellow is expected to become facile with retina laser treatment for a wide breadth of vitreoretinal pathology. Intravitreal injections, cryopexy of peripheral retinal pathology and other basic procedures are mastered. Additionally, the first year fellow will have ample opportunity to learn vitrectomy, endolaser, and retinal detachment repair techniques. Diagnostic and treatment modalities available include fundus photography, fluorescein angiography, new generation OCT (OCT-A and intraoperative OCT), ICG, A-and B-scan ultrasonography, electrophysiological testing, PASCAL, and micropulse lasers. Opportunities are provided for ample experience in each of these areas.

The first year fellow is strongly encouraged to spend time in clinical research. Opportunities exist for involvement in clinical research projects and travel to national meetings. Fellows are encouraged to produce several manuscripts during each year of the fellowship. Additionally, fellows are listed as sub-investigators on clinical trials.

The Second Year:

During the second year of the fellowship, in addition to the activities outlined above, the fellow has the opportunity to assume primary responsibility for the management and treatment of complex vitreoretinal pathology in the clinic and OR. The fellows are expected to continue research started during the first year, present data at national meetings, and submit research for publication.
We Asked Current and Graduated Fellows: “What are 15 Vitreoretinal Fellowship Attraction Points?”

- Dr. Hariprasad – The program director’s training at Wash U / Barnes and teaching fellows the "Barnes way".
- Exposure to cutting-edge diagnostic technologies such as OCT-A and intraoperative OCT.
- High volume of vitreoretinal procedures and cases.
- Top notch surgical equipment (Constellation Vitrectomy System + New Leica Microscope w/ HD Video and Monitors + True Vision 3D System).
- Strong emphasis on learning the business aspects of retina and how to efficiently run a retina clinic and OR.
- ROP and pediatric retina experience with Dr. Blair, Dr. Rodriguez, and Dr. Warren.
- Exposure to different Chicago hospital systems.
- Fellows are sub-investigators on all clinical trials, which is of tremendous value after graduation since the trials may be brought to the fellows’ respective practices/institutions.
- The U of C network of fellows, which continues to grow and spans the entire country geographically (New York to California). EXCELLENT job placement after graduation (both academic and private institutions) with tremendous faculty support to get your dream job.
- Clinical research - Fellows are exposed to and take part in several studies. Also, the program provides several individual research opportunities. Fellows are encouraged to apply for various research awards.
- The opportunity to attend major retina meetings and investigator meetings for clinical trials (ASRS, Retina Society, ARVO, Vit Buckle Society, etc.).
- Very reasonable call schedule - Able to enjoy weekends without excessive calls. Much resident support for call coverage.
- Camaraderie of the fellowship program – The program director and other attending’s treat fellows like family. The program also fosters much camaraderie among fellows, residents, and medical students.
- Reputation of the University of Chicago as well as excellent support staff, facilities, and happy work environment.
- The city of Chicago is the “FOVEA of the United States” – Given citywide Rabb Retina Society Meetings, internationally recognized retina faculty throughout the city, AVTT Retina Fellows’ Meeting, Retina Fellows’ Mid-Year Forum, Chicagoland Retinal Update Meeting, AAO, quarterly dinner events for Chicago retina fellows, etc.
SEENU M. HARIPRASAD, MD

Shui-Chin Lee Endowed Professor
Ophthalmologist-in-Chief and Chair
Director, Fellowship in the Diseases and Surgery of the Retina, Macula, and Vitreous

Effective July 1, 2023, Dr. Seenu M. Hariprasad, MD, the Shui-Chin Lee Professor of Ophthalmology, was appointed Chair of the Department of Ophthalmology and Visual Science. Dr. Hariprasad has been serving as Interim Chair since 2020.

Dr. Hariprasad is an internationally recognized vitreoretinal surgeon who originally joined the University of Chicago in 2005. Over the course of his career, he has developed a strong track record as a clinician, surgeon, researcher, educator, and leader in his department. He is a leading specialist in various vitreoretinal disorders, including macular degeneration, diabetic eye disease, intraocular infection, and retinal vein occlusions. He has implemented more effective and efficient sutureless microincisional vitrectomy techniques at the medical center, and his clinical research has contributed to the understanding and use of new medications to combat a wide variety of vitreoretinal disorders.

Dr. Hariprasad has served as an investigator in more than 45 national and international retina clinical trials evaluating various medications, sustained drug-delivery devices, and surgical innovations. His work has led to over 300 peer-reviewed publications, meeting abstracts and textbook chapters, including Management of Retinal Vein Occlusion: Current Concepts, one of only a small number of textbooks dedicated to this disease.

In addition to his clinical and research activities, Dr. Hariprasad has been an active contributor to his field, serving as an Executive Editor of the American Journal of Ophthalmology. He has received numerous honors, including the American Academy of Ophthalmology Achievement Award, the American Society of Retina Specialists Senior Honor Achievement and Crystal Apple Awards, the J. Donald Gass, MD, Beacon of Sight Award, the Baylor College of Medicine James Key Award, Becker’s 135 Leading Ophthalmologists in America, and the Retina Congress of India Gold Medal. Ophthalmology Retina, an American Academy of Ophthalmology journal, listed his research as one of the “100 Most Cited Articles on Vitrectomy from 1971 to 2018.” He is also included in the Retina Hall of Fame and has been named consistently as a top doctor in publications such as US News & World Report and Chicago magazine.

Clinical Interests
- Age-related macular degeneration
- Diabetic eye diseases
- Retinal vein occlusions
- Epiretinal membrane
- Endophthalmitis
- Vitreous hemorrhage
- Retinal detachment
Dimitra Skondra, an internationally renowned vitreoretinal surgeon and physician scientist, is an Associate Professor Ophthalmology & Visual Science and the Director of the Terry Ernest Ocular Imaging Center. She is also the founder and leader of UChicago Retinal Microbiome and UChicago Retina Big Data/Bioinformatics team. She completed her ophthalmology residency at Weill Cornell Medical College/New York Presbyterian Hospital and her PhD/postdoctoral fellowship and vitreoretinal surgery fellowship at Harvard Medical School.

Her team focuses on the role of gut microbiome in retinal disorders in particular AMD and ROP. She is considered one of the international leaders and pioneers in this newly emerged field of retinal research using specialized gnotobiotic animal models she has developed and cutting-edge multi-omics approach to delineate the gut-retina axis interactions. Her team, using Big-Data and computational bioinformatics approach is also studying repurposing of known medications for AMD and other retinal and ocular disorders and her work has shown that metformin, a common anti-diabetic medication is protective for AMD and could represent a new therapeutic strategy for AMD.

She is an elected member of the prestigious Macula Society, Retina Society and Club Jules Gonin that include selected leaders of the retinal field internationally. She has received numerous honors and awards including ARVO Early Career Clinician Scientist, Retina Society Margherio Award, Club Jules Gonin Retina Research Foundation award, ISPB AMD award and has given multiple invited lectures nationally and internationally. She is an invited founding member of International Ocular Circulation Society and the Microbiome Medicine Program, on editorial board of IOVS and Nature’s Scientific Reports and has been elected in retinal section of ARVO Program Committee and Retina’s Society Socioeconomic Committee.

**Clinical Interests**
- Age-related macular degeneration
- Diabetic eye diseases
- Retinal vein occlusions
- Macular hole, trauma
- Epiretinal membrane
- Proliferative vitreoretinopathy
- Complex diabetic retinal detachment
- Intraocular infection
- Microbiome
Alexis K. Warren, MD is the newest appointed Assistant Professor of Ophthalmology and Visual Science at The University of Chicago and also serves as the first Vice-Chair for Diversity Equity and Inclusion/Wellness Director for the department. She most recently completed her training at one of the busiest medical centers in the city of Chicago during which time she was privileged enough to train under world renown retinal surgeons to develop her skills and expertise in complex retinal detachment repairs, diabetic eye disease, age-related macular degeneration, macular holes, epiretinal membranes, retinopathy of prematurity and posterior uveitis.

Throughout her training she was also able to get involved with clinical trials, new techniques for surgical innovation and research on a wide variety of topics from artificial intelligence to health care disparities. Dr. Warren is active in the various ophthalmologic subspecialty societies and devotes much of her time outside of her clinical practice to physician advocacy, mentorship and teaching. She continues to be recognized for her efforts and was most recently chosen by Retina Today as a Rising Star in Retina Honoree, an award chosen by leaders in the field to highlight the top retina fellows in the country.

Dr. Warren is very committed to advancing the field of ophthalmology and specifically to retinal specialists and as such served as the appointed chair of the Fellows in Training Section for the America Society of Retinal Specialists during which time she helped to organize and moderate surgical grand rounds, debates, and career discussions for other trainees across the country. She was also invited to join the American Academy of Ophthalmology’s Task Force to address disparities in eyecare resulting in authorship in the Ophthalmology journal.

Dr. Warren received her medical degree from the University of Kansas in her hometown of Kansas City. She then completed her residency at one of the top institutions in the country at the University of Iowa Hospitals and Clinics. She most recently completed her two-year vitreoretinal fellowship at the University of Illinois Eye and Ear Infirmary.
MICHAEL P. BLAIR, MD

Clinical Associate Professor
Department of Ophthalmology & Visual Science

Practice Locations
- University of Chicago Medicine
  5758 S. Maryland Avenue
  Chicago, IL 60637

- Retina Consultants Ltd.
  2454 E. Dempster St., Suite 400
  Des Plaines, IL 60016

Clinical Interests
- Vitreoretinal Surgery, Trauma
- Pediatric Retina
- Retinopathy of Prematurity

SHAUN ITTIARA, MD

Clinical Associate Professor
Department of Ophthalmology & Visual Science

Practice Location
- University of Chicago Medicine
  5758 S. Maryland Avenue
  Chicago, IL 60637

- Retinal Vitreal Consultants
  2600 S Michigan Avenue
  Chicago, IL 60616

Clinical Interests
- Vitreoretinal surgery
- Diabetic retinopathy
- Secondary IOL placement
Meet the Faculty

PAULPOJ CHIRANAND, MD

Clinical Associate Professor
Department of Ophthalmology & Visual Science

Practice Locations
- Retinal Vitreal Consultants
  2600 S Michigan Avenue
  Chicago, IL 60616
- Edward Hines, Jr. VA Hospital
  5000 5th Ave,
  Hines, IL 60141
- University of Chicago Medicine
  5758 S. Maryland Avenue
  Chicago, IL 60637

Clinical Interests
- Vitreoretinal surgery
- Age-related Macular Degeneration
- Diabetic retinopathy

SARAH RODRIGUEZ, MD, MPH

Associate Professor
Department of Ophthalmology & Visual Science

Practice Locations
- University of Chicago Medicine
  5758 S. Maryland Avenue
  Chicago, IL 60637

Clinical Interests
- Amblyopia
- Pediatric & adult strabismus
- Pediatric cataracts
- Retinopathy of prematurity
Current Fellows (2023-2024)

1st Year Vitreoretinal Surgery Fellow

Madeleine Yehia, MD
Uveitis Fellowship: University of Illinois in Chicago, Chicago, Illinois

2nd Year Vitreoretinal Surgery Fellow

Reem Gonnah, MD
Residency: Saint Louis University
Fellowship Alumni

Joseph Benevento, MD  
(2005-2007)  
Oschner Medical Center  
New Orleans, LA

Richard Lin, MD  
(2006-2008) 
Scripps Memorial Hospital  
La Jolla, CA

Theodore Lin, MD  
(2007-2009)  
Inland Valley Retina, Inc.  
Corona, CA

Veeral Sheth, MD, FACS  
(2008-2010)  
Director of Clinical Research  
University Retina and Macula Associates  
Oak Forest, IL  
Clinical Assistant Professor  
University of Illinois at Chicago

Paulpoj Chiranand, MD  
(2009-2011)  
Retinal Vitreal Consultants, Ltd.  
Chicago, IL

Ravi D. Patel, MD  
(2010-2012)  
Keystone Eye Associates  
Philadelphia, PA
Fellowship Alumni

Shaun Ittiara, MD
(2011-2013)
Retinal Vitreal Consultants, Ltd.
Chicago, IL

Jose Garcia-Gonzalez, MD
(2012-2014)
Retinal Consultants Ltd.
Des Plaines, IL

Shaun Lewis, MD
(2013-2015)
Retina Associates of Cleveland
Cleveland, OH

Ankur Shah, MD
(2014-2016)
Prairie Eye & LASIK Center
Springfield, IL

Raj N. Patel, MD
Carolina Ophthalmology, P.A.
Asheville, NC

Liliya Golas, MD
(2016-2018)
Martel Eye Medical Group
Sacramento, CA

Sidney Schechet, MD
(2017-2019)
Elman Retina Group
Baltimore, MD

Rahul Komati, MD
(2018-2020)
Georgia Retina
Atlanta, GA
Fellowship Alumni

Anna Mackin, MD
(2019-2021)
Vistar Eye Center
Roanoke, VA

David Dao, MD
(2020-2022)
Elman Retina Group
Baltimore, MD

Lincoln Shaw, MD
(2021-2023)
Retina & Vitreous Consultants of WI
Kenosha, WI
Honors & Awards

Dr. Schechet presenting his finalist video at the 2019 Vit Buckle Society Fellows Foray

Dr. Mackin presenting her research as a finalist at the 2019 Ophthalmology Times Research Scholar Program

The Crystal Apple award for excellence in teaching and mentorship, presented to Dr. Hariprasad at the ASRS 2019 Meeting

Dr. Hariprasad posing with Dr. Komati and his 1st place “Fellow Games” trophy from the 2020 Retina Fellows Forum

Dr. Schechet receiving the AAO 2018 Young Ophthalmologist award for his video on wine glass injury with a “toast”
WHERE IT ALL BEGAN

As a child, Dr. Mackin was captivated by her parents’ clinical and research work—her father is an orthopedic surgeon, and her mother is a clinical pathologist. She was determined to one day be a physician, too. She received a bachelor’s degree with distinction in biochemistry and integrative physiology and attended medical school at the University of Colorado. Several of Dr. Mackin’s core clinical rotations took place in underserved rural counties in south-central Colorado, which gave her a great appreciation for the desperate need for care among rural communities.

HER PATH TO RETINA

Dr. Mackin quickly realized that ophthalmology was her career aspiration during medical school clinical rotations. She remembers the feeling of curiosity and awe when examining the eye in search of the answer to the patient’s symptoms; she still feels this way when examining a patient. She helped to research novel therapeutic approaches to AMD with her mentor, Jeffrey Olson, MD. This was only the beginning of her discovery that exciting therapies and diagnostic techniques play an integral role in the everyday practice of vitreoretinal surgery. Once in residency at the University of Colorado, Dr. Mackin was drawn to the complex and diverse pathology of retinal diseases. Residency at UCHealth Sue Anschtutz-Rodgers Eye Center exposed her to the full gamut of vitreoretinal pathologies, including inherited retinal disease, pediatrics, ocular oncology, and uveitis, confirming her decision to dedicate her career to the field of retina.

Dr. Mackin matched at her number one program, the Snyder Family Endowed Fellowship in vitreoretinal surgery at the University of Chicago.

SUPPORT ALONG THE WAY

Dr. Mackin is forever grateful to her residency and fellowship mentors for teaching her invaluable clinical and surgical skills and providing guidance and support on her professional journey. She would like to extend a special thank you to her fellowship director, Seenu M. Hariprasad, MD, for teaching the medical side of patient care and emphasizing efficiency and cost-consciousness. Every time Dr. Mackin is in the OR, she hears Dr. Hariprasad’s voice, urging her to make every second of the surgery count. Dr. Hariprasad also taught her the importance of industry collaboration. Working closely with industry allows clinicians to bring the interests of patients to the forefront of clinical discovery and ensures that everyday clinical experiences can lead to safer and more effective therapies for the community at large.

AN EXPERIENCE TO REMEMBER

During Dr. Mackin’s first night of attending call, she took care of a monocular patient with an acute retinal detachment in his good eye. The surgery went well, and the patient regained his sight and independence. She was honored to use her skills to make such a difference and provide sight-saving care at that time and every day since. Many of her patients travel more than an hour to see a retina specialist, and it is rewarding to care for a community in need.
Fellowship Bibliography

**PEER-REVIEWED ARTICLES**


Contralateral amaurosis after a retrobulbar block. Williams B, Schechet SA, Hariprasad I, Shah H, Golas L, Hariprasad SM.


Fellowship Bibliography


Lin, H., Dao, D. & Sen, H. N. Diagnosis and treatment of autoimmune retinopathy. Inflammation 5, 16 (2020)


NON-PEER REVIEWED

Fellowship Bibliography


MEETING PRESENTATIONS


Fellowship Bibliography


Patel RD, Hariprasad SM: The BRAVO and CRUISE Trials; What Have We Learned One Year Later? Web Article for the American Society of Retina Specialists. 2011.


Fellowship Bibliography


Theophanous C, Schechet S, Hilbert Rodriguez S, Blair M: Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant with Retinopathy of Prematurity. ROP Hot Topics, Chicago, IL, Oct 2018


Fellowship Bibliography

Dao DT, Bernstein SL (2018). “Effect of a Novel Immunomodulatory Drug (Stradomer) on a Model of Neovascular AMD.” Oral Presentation at University of Maryland Richard D Richards Annual Research Symposium; June 2, 2018; Baltimore, MD.


BOOK CHAPTERS


CLINICAL TRIALS

Regeneron, An Exploratory Study of the Safety, Tolerability and Biological Effect of Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration (VGFT-00502), 2005-2008.

Allergan, DME, A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700µg and 350µg Dexamethasone Posterior Segment Drug Delivery System (Dex PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema), 2005-2009.

Alimera Sciences, A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Edema, 2005-2009.


Allergan, A Six-months, Phase III, Multicenter, Randomized, Sham-Controlled Trial (With Six-months Open-Label Extension) to Assess the Safety and Efficacy of 700 ul and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion, 2005-2009.

NIH/NEI, The SCORE Study: A Randomized Trial to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema Associated With Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion, 2005-2009.


Eyetech Pharmaceuticals, A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of 0.3, 0.03 or 0.003 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula, 2005-2007.

Regeneron, A Randomized Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration Clinical Evaluation of Anti-Angiogenesis in the Retina Intravitreal Trial AMD Phase 2 (CLEAR-IT AMD-2), 2006-2008.

Alcon Pharmaceuticals, Nevanac, Determination of Aqueous and Vitreous Concentration of Topically Administered Nepafenac 0.1% (Nevanac) and Ketorolac 0.4% (Acular LS) in Humans, 2006-2007.

National Eye Institute, The Age-Related Eye Disease Study 2 (AREDS 2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids [Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)] in Age-Related Macular Degeneration, 2006-2007.

Novartis, In Sight CNV Registry – Longitudinal Database to Capture Patient Demographics and Treatment Outcomes in Patients with CNV due to AMD, 2006-2007.


Genentech, A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE), 2008-2010.

Genentech, A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO), 2008-2010.

Pfizer, A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy and Safety of PF-04523655 Versus Laser Therapy (DEGAS), 2009-2011.

Glaxo Smith Kline, Pattern of Treatment for Wet AMD and Health Outcomes of Anti-VEGF Therapy in Ophthalmic Clinics in the US: a Medical Chart Review (PRACTICE), 2009-2010.

Genentech, A Study of Ranibizumab Administered Monthly or on an As-Needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR), 2010-2012.

Genentech, Principal Investigator, A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion (SHORE), 2011-2013.

Fovea Pharmaceuticals, Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy, 2011-2012.


Lpath / Pfizer Pharmaceuticals, Efficacy and Safety Study of iSONEP With and Without Lucentis/Avastin to Treat Age-related Macular Degeneration (AMD) (Nexus), 2012-2015.

XOMA, Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis (EYEGUARD™-A), 2013-2016.

XOMA, Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment (EYEGUARD™-C), 2013-2016.

Santen, A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis (SAKURA), 2015-2016.


The Microbiome and Eye Disease Study (MBED). University of Chicago. Principle investigator: Dimitra Skondra, MD, PhD. April 2021-present.


Kodiak Sciences. A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR). June 2022-2023.

**VIDEO PUBLICATIONS**


